Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

被引：0
|
作者：
Edoardo Caronna
Victor José Gallardo
Alicia Alpuente
Marta Torres-Ferrus
Patricia Pozo-Rosich
机构：
[1] Universitat Autònoma de Barcelona,Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine
[2] Universitat Autònoma de Barcelona,Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Migraine; Medication overuse; CGRP; Monoclonal antibodies; Erenumab; Galcanezumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
    Pensato, Umberto
    Baraldi, Carlo
    Favoni, Valentina
    Mascarella, Davide
    Matteo, Eleonora
    Andrini, Giorgia
    Cainazzo, Maria Michela
    Cortelli, Pietro
    Pierangeli, Giulia
    Guerzoni, Simona
    Cevoli, Sabina
    CEPHALALGIA, 2022, 42 (07) : 645 - 653
  • [42] Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
    Piero Barbanti
    Gabriella Egeo
    Cinzia Aurilia
    Claudia Altamura
    Florindo d’Onofrio
    Cinzia Finocchi
    Maria Albanese
    Marco Aguggia
    Renata Rao
    Maurizio Zucco
    Fabio Frediani
    Massimo Filippi
    Roberta Messina
    Sabina Cevoli
    Antonio Carnevale
    Giulia Fiorentini
    Stefano Messina
    Francesco Bono
    Paola Torelli
    Stefania Proietti
    Stefano Bonassi
    Fabrizio Vernieri
    The Journal of Headache and Pain, 2022, 23
  • [43] Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
    Barbanti, Piero
    Egeo, Gabriella
    Aurilia, Cinzia
    Altamura, Claudia
    D'Onofrio, Florindo
    Finocchi, Cinzia
    Albanese, Maria
    Aguggia, Marco
    Rao, Renata
    Zucco, Maurizio
    Frediani, Fabio
    Filippi, Massimo
    Messina, Roberta
    Cevoli, Sabina
    Carnevale, Antonio
    Fiorentini, Giulia
    Messina, Stefano
    Bono, Francesco
    Torelli, Paola
    Proietti, Stefania
    Bonassi, Stefano
    Vernieri, Fabrizio
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
  • [44] Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
    Pilati, Laura
    Torrente, Angelo
    Di Marco, Salvatore
    Ferlisi, Salvatore
    Notaro, Giulia
    Romano, Marika
    Alonge, Paolo
    Vassallo, Lavinia
    Ferrau, Ludovica
    Autunno, Massimo
    Grugno, Rosario
    Camarda, Cecilia
    Brighina, Filippo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
  • [45] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review
    Salim, Amira
    Hennessy, Elise
    Sonneborn, Claire
    Hogue, Olivia
    Biswas, Sudipa
    Mays, Maryann
    Suneja, Aarushi
    Ahmed, Zubair
    Mata, Ignacio F.
    CNS DRUGS, 2024, 38 (06) : 481 - 491
  • [46] Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study
    Alpuente, Alicia
    Torre-Sune, Anna
    Caronna, Edoardo
    Gine-Cipres, Eulalia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    CEPHALALGIA, 2023, 43 (08)
  • [47] Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis
    Haridas, Mundot Puliappadamb
    Tripathy, Amruta
    Maiti, Rituparna
    Srinivasan, Anand
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2024, 22 (01) : 23 - 32
  • [48] Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
    Montisano, Danilo Antonio
    Giossi, Riccardo
    Canella, Mattia
    Altamura, Claudia
    Marcosano, Marilena
    Vernieri, Fabrizio
    Raggi, Alberto
    Grazzi, Licia
    TOXINS, 2024, 16 (04)
  • [49] A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
    Kielbasa, William
    Helton, Danielle L.
    CEPHALALGIA, 2019, 39 (10) : 1284 - 1297
  • [50] Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review
    Munoz-Vendrell, Albert
    Lopez-Bravo, Alba
    Layos-Romero, Almudena
    Alberola-Amores, Francisco J.
    Caballero, Maria Obdulia Lozano
    Sanchez-Soblechero, Antonio
    Morales-Hernandez, Cristian
    Castro-Sanchez, Maria Victoria
    Navarro-Perez, Maria Pilar
    Cordova-Infantes, Maria Rocio
    Caronna, Edoardo
    Irimia, Pablo
    Gonzalez-Martinez, Alicia
    Jr Headache Grp Spanish Soc Neurology jGECSEN
    PAIN MANAGEMENT, 2025, 15 (03) : 161 - 171
12345